Trials / Recruiting
RecruitingNCT05988216
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
A Clinical Study on the Safety and Efficacy of BRL-301 (Allogeneic Chimeric Antigen Receptor T Cell Injection Targeting CD19 Gene) in the Treatment of Refractory Systemic Lupus Erythematosus
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.
Detailed description
The study had the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation \& Lymphodepleting Chemotherapy), Treatment and Follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BRL-301 | Single dose of Allogeneic Anti-CD19 CAR T cells will be infused |
Timeline
- Start date
- 2023-08-14
- Primary completion
- 2024-12-01
- Completion
- 2025-09-01
- First posted
- 2023-08-14
- Last updated
- 2024-09-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05988216. Inclusion in this directory is not an endorsement.